Cosmetic giant L’Oreal is teaming up with with Organovo, a company that “designs and creates multicellular, dynamic, and functional human tissues to create artificial human skin to use in product testing. According to Guive Balooch, the global vice…
As new member of the NYSE, Organovo rang the opening bell this morning. Last week the stock stock increased 55% after its new NYSE listing.
In this video, CBC News interviews Organovo’s CEO Keith Murphy to learn more about bioprinting, and in particular, how the quest to print an entire human liver is going.
Bioprinting is advancing at an increasing pace. Now, with living liver tissue being printed in 3D without scaffolds, Organovo should be knocking on the FDA’s door any day now.
With so much interest (and so much misinformation) in 3D printer-related stocks, it’s time to update readers on the subject of investing in 3D printing companies.
Something is going on with bioprinting pioneer Organovo (ONVO) stock shares the last few days — they have woken up from a six month slumber. Shares are rising on heavy volume.
The Dr. Frankensteins at Organovo have been bioprinting with code-based programs; they desperately need a real user interface that will speed up the process of biodesigning.
Gabor Forgacs, co-founder of Modern Meadow, demonstrates that bioprinting real meat is both feasible and tasty.
Bioprinting pioneer Organovo and CAD software king Autodesk are working together to create the bioprinting CAD software of the future.
Futurist Christopher Barnatt of Explaining the Futre has some fascinating predictions about the future of 3D printing, and in particular bioprinting.